AIRQ 3-Month Differentiates Asthma Control Similarly to 12-Month Version
The 3-month Asthma Impairment and Risk Questionnaire (AIRQ™) demonstrated a similar ability to differentiate asthma control as the 12-month AIRQ.
The 3-month Asthma Impairment and Risk Questionnaire (AIRQ™) demonstrated a similar ability to differentiate asthma control as the 12-month AIRQ.
The effect of coronavirus disease 2019 (COVID-19) on patients with food allergy and their parents and caregivers is substantial.
An exhalation delivery system appears to more effectively apply topical steroids to nasal polyps located in the ostiomeatal complex.
Women with chronic cough in the United States and United Kingdom were more likely to have a higher number of cough triggers.
Because of the prevalence of behavioral health issues in elderly patients with asthma, appropriate behavioral health treatment may improve patient outcomes.
The safety and efficacy of crisaborole ointment, 2%, was examined in pediatric patients with mild to moderate atopic dermatitis with and without comorbid allergic rhinitis.
Adding reslizumab to mometasone furoate enhanced clinical benefits of the intranasal corticosteroid alone in patients with uncontrolled chronic rhinosinusitis with nasal polyps and peripheral eosinophilia.
Patients with asthma that is poorly controlled by ICS/LABA therapy may experience improvement in lung function with the addition of umeclidinium and/or doubling of the corticosteroid fluticasone furoate.
Treatment with monoclonal antibody and dual IL-4/IL-13 inhibitor dupilumab was well tolerated and associated with sustained improvement in asthma control for up to 96 weeks
Larger skin flare results in pediatric patients correlated to failing certain oral food challenges, but were not predictive of requiring epinephrine.